Paper25614280
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD and 5 others. Arterioscler Thromb Vasc Biol, 2015. Cited by 164 papers, by iCite.
Cite this record
ConductScience Library. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Papers, record 25614280. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25614280
- Disease
- coronary artery disorder241 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticholesteremic Agents | Major topic |
| Apolipoprotein B-100 | Major topic |
| Hyperlipoproteinemia Type II | Major topic |
| Lipoprotein(a) | Major topic |
| Oligodeoxyribonucleotides, Antisense | Major topic |
| Oligonucleotides | Major topic |
| Adult | |
| Aged | |
| Biomarkers | |
| Cardiovascular Diseases | |
| Clinical Trials, Phase III as Topic | |
| Down-Regulation | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Randomized Controlled Trials as Topic | |
| Risk Assessment | |
| Risk Factors | |
| Treatment Outcome |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 HL088093 | NHLBI NIH HHS | United States | P01HL088093 | PubMed and NIH | NIH RePORTER |
| U54 HL119893 | NHLBI NIH HHS | United States | U54HL119893 | PubMed and NIH | NIH RePORTER |
| P01-HL088093 | NHLBI NIH HHS | United States | P01HL088093 | PubMed and NIH | NIH RePORTER |
| U54-HL119893 | NHLBI NIH HHS | United States | U54HL119893 | PubMed and NIH | NIH RePORTER |
| R01-HL093767 | NHLBI NIH HHS | United States | R01HL093767 | PubMed and NIH | NIH RePORTER |
| R01-HL119828 | NHLBI NIH HHS | United States | R01HL119828 | PubMed and NIH | NIH RePORTER |
| R01 HL119828 | NHLBI NIH HHS | United States | R01HL119828 | PubMed and NIH | NIH RePORTER |
| P01 HL055798 | NHLBI NIH HHS | United States | P01HL055798 | PubMed and NIH | NIH RePORTER |
| P01-HL055798 | NHLBI NIH HHS | United States | P01HL055798 | PubMed and NIH | NIH RePORTER |
| R01 HL093767 | NHLBI NIH HHS | United States | R01HL093767 | PubMed and NIH | NIH RePORTER |
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00607373 | Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00706849 | Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00770146 | Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00794664 | Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis | Derived from the trial | Yes | ClinicalTrials.gov |
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23060426 | Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. | Circulation | 2012 | https://conductscience.org/library/papers/23060426 | PubMed |
| 2 | 22969153 | Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. | J Lipid Res | 2012 | https://conductscience.org/library/papers/22969153 | PubMed |
| 3 | 23065826 | Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. | Arterioscler Thromb Vasc Biol | 2012 | https://conductscience.org/library/papers/23065826 | PubMed |
| 4 | 23152839 | Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. | PLoS One | 2012 | https://conductscience.org/library/papers/23152839 | PubMed |
| 5 | 23041907 | Emerging therapeutic agents to lower lipoprotein (a) levels. | Curr Opin Lipidol | 2012 | https://conductscience.org/library/papers/23041907 | PubMed |
| 6 | 23099120 | In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). | Atherosclerosis | 2012 | https://conductscience.org/library/papers/23099120 | PubMed |
| 7 | 10669652 | Lipoprotein(a) in homozygous familial hypercholesterolemia. | Arterioscler Thromb Vasc Biol | 2000 | https://conductscience.org/library/papers/10669652 | PubMed |
| 8 | 11230837 | Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. | Am J Cardiol | 2001 | https://conductscience.org/library/papers/11230837 | PubMed |
| 9 | 12575961 | Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. | J Am Coll Cardiol | 2003 | https://conductscience.org/library/papers/12575961 | PubMed |
| 10 | 14578310 | Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. | Clin Chem | 2003 | https://conductscience.org/library/papers/14578310 | PubMed |
| 11 | 14739118 | Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). | Arterioscler Thromb Vasc Biol | 2004 | https://conductscience.org/library/papers/14739118 | PubMed |
| 12 | 15184281 | Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. | Circulation | 2004 | https://conductscience.org/library/papers/15184281 | PubMed |
| 13 | 15353498 | High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. | Circulation | 2004 | https://conductscience.org/library/papers/15353498 | PubMed |
| 14 | 2530005 | HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. | Circulation | 1989 | https://conductscience.org/library/papers/2530005 | PubMed |
| 15 | 2139920 | Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. | N Engl J Med | 1990 | https://conductscience.org/library/papers/2139920 | PubMed |
| 16 | 8280186 | The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. | Atherosclerosis | 1993 | https://conductscience.org/library/papers/8280186 | PubMed |
| 17 | 7495281 | Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. | Am J Pathol | 1995 | https://conductscience.org/library/papers/7495281 | PubMed |
| 18 | 9017509 | Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. | J Lipid Res | 1996 | https://conductscience.org/library/papers/9017509 | PubMed |
| 19 | 23174369 | Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. | Atherosclerosis | 2013 | https://conductscience.org/library/papers/23174369 | PubMed |
| 20 | 22998429 | Lipoprotein(a): resurrected by genetics. | J Intern Med | 2013 | https://conductscience.org/library/papers/22998429 | PubMed |
Cited by88
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 164 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42973626 | Advances in therapeutic oligonucleotide conjugates. | AAPS Open | 2026 | https://conductscience.org/library/papers/42973626 | PubMed |
| 42133095 | Targeting PCSK9, APOB, and CETP at the Transcriptome Level by hsa-miR-30b-3p Reduces LDL-Associated Protein in Huh-7 Cells. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42133095 | PubMed |
| 42032080 | Tissue-selective COPII modulator SEC16B aggravates cardiovascular disease by promoting lipid export. | EMBO J | 2026 | https://conductscience.org/library/papers/42032080 | PubMed |
| 41803448 | Advances in computational prediction of RNA-small molecule binding affinity. | J Comput Aided Mol Des | 2026 | https://conductscience.org/library/papers/41803448 | PubMed |
| 41660526 | A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions. | J Lipid Atheroscler | 2026 | https://conductscience.org/library/papers/41660526 | PubMed |
| 41621836 | RNA-Based Therapies for Inherited Metabolic Disorders. | J Inherit Metab Dis | 2026 | https://conductscience.org/library/papers/41621836 | PubMed |
| 41560299 | A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions. | Korean Circ J | 2026 | https://conductscience.org/library/papers/41560299 | PubMed |
| 41346702 | The efficacy of oligonucleotide-based gene therapeutics in gene silencing. | Theranostics | 2026 | https://conductscience.org/library/papers/41346702 | PubMed |
| 40968429 | Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a). | Cardiovasc Hematol Disord Drug Targets | 2026 | https://conductscience.org/library/papers/40968429 | PubMed |
| 40654252 | Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/40654252 | PubMed |
| 40487670 | Inhaled non-viral delivery systems for RNA therapeutics. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/40487670 | PubMed |
| 40026530 | Could the Hemodynamic Progression of Aortic Valve Stenosis be Slowed Pharmacologically? The Unsolved Dilemma. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40026530 | PubMed |
| 39934773 | Lipid-lowering drug targets associated with risk of respiratory disease: a Mendelian randomization study. | BMC Pulm Med | 2025 | https://conductscience.org/library/papers/39934773 | PubMed |
| 39756980 | New Approaches to Lipoproteins for the Prevention of Cardiovascular Events. | J Atheroscler Thromb | 2025 | https://conductscience.org/library/papers/39756980 | PubMed |
| 39598201 | The Impact of Diet on Lipoprotein(a) Levels. | Life (Basel) | 2024 | https://conductscience.org/library/papers/39598201 | PubMed |
| 39476283 | Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials. | High Blood Press Cardiovasc Prev | 2025 | https://conductscience.org/library/papers/39476283 | PubMed |
| 39385797 | Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients. | Transl Med UniSa | 2024 | https://conductscience.org/library/papers/39385797 | PubMed |
| 39302109 | Lipoprotein(a) and cardiovascular disease. | Biochem J | 2024 | https://conductscience.org/library/papers/39302109 | PubMed |
| 38878139 | Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis. | Curr Atheroscler Rep | 2024 | https://conductscience.org/library/papers/38878139 | PubMed |
| 38542510 | Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand? | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542510 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| LDLR | 3949 | PubTator's text mining | https://conductscience.org/library/genes/3949 | NCBI Gene |
| LPA | 4018 | PubTator's text mining | https://conductscience.org/library/genes/4018 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| MIPOMERSEN | CHEMBL2219536 | Derived from the trial | 4 | https://conductscience.org/library/drugs/CHEMBL2219536 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25614280
GET https://conductscience.org/api/papers/v1/25614280/references?page=2